Becton, Dickinson and Company (BD) has officially closed the book on a landmark fiscal year, reporting a 4.9% year-over-year revenue increase to $19.5bn for fiscal year 2026 (FY26). This financial milestone, released on 5 November 2026, marks more than just a successful set of earnings; it represents the first full-year realization of the company’s strategic pivot toward a leaner, more specialized medical technology powerhouse.
The centerpiece of this transition—the $17.5bn spin-off and merger of its diagnostics business with Waters Corporation—has fundamentally altered the company’s operational profile. As BD enters FY27, it stands as a streamlined entity, shedding legacy segments to prioritize high-growth medtech innovation.
The Strategic Pivot: Unpacking the $17.5bn Divestiture
For decades, BD was synonymous with a sprawling portfolio that encompassed everything from basic medical supplies to complex clinical diagnostics. However, the market landscape in the post-pandemic era necessitated a change. In June 2025, BD announced its intention to divest its Biosciences and Diagnostic Solutions business, effectively placing its diagnostic assets into the hands of Waters Corporation.
The transaction, which reached its final completion in February 2026, was not merely a sale; it was a repositioning. By offloading a business unit that, while stable, operated on a different growth trajectory than its core medtech offerings, BD has successfully streamlined its balance sheet.
Why the Split?
GlobalData analysts who scrutinized the deal at the time of its inception noted that the diagnostics unit was a steady performer, generating approximately $3.3bn in annual revenue with a consistent 5% growth rate between 2019 and 2024. More importantly, the unit was characterized by its durability—with roughly 80% of its revenue considered "recurring" due to a vast installed base and a constant need for consumables, reagents, and specialized service.
By removing this segment, BD has intentionally moved away from the high-capital, high-maintenance diagnostic space, choosing instead to double down on medical delivery systems, interventional technologies, and connected care solutions. This allows the company to reallocate capital and management focus toward sectors where it holds a dominant market share and can drive superior margins.
Fiscal Year 2026: A Chronology of Progress
The journey to the FY26 financial results was marked by several critical operational phases that shaped the company’s trajectory:
- June 2025: BD officially announces the $17.5bn merger agreement with Waters Corporation, signaling the beginning of the end for its diagnostic arm.
- Q3–Q4 2025: The company begins the complex regulatory and operational separation of its workforce, supply chains, and IT infrastructure.
- February 2026: The transaction is finalized. BD enters the second half of its fiscal year as a pure-play medtech entity.
- November 2026: BD reports FY26 total revenues of $19.5bn, with a strong Q4 performance of $5.3bn, representing a 5.4% increase over the previous year.
- November 5, 2026: Following the earnings release, the company’s stock on the NYSE shows resilience, climbing to $214.04 as investor confidence in the “New BD” strategy solidifies.
Segment Performance: Where the Growth Lies
The revenue breakdown for FY26 highlights the efficacy of BD’s current portfolio. Despite the removal of the diagnostic segment, the company’s remaining core businesses demonstrated robust organic growth:
1. Medical Essentials: The Backbone
The Medical Essentials segment remains the primary engine of BD’s financial stability. Generating approximately $3.9bn in revenue, it recorded a 4.6% year-over-year growth. This sector benefits from the high-volume nature of BD’s foundational products, which are staples in hospitals globally.
2. Interventional Technologies
Following closely behind was the Interventional segment, which posted an impressive 6.7% growth to reach $3.8bn. This segment is crucial to BD’s long-term strategy, as it focuses on high-acuity surgical and interventional tools that command higher pricing power and reflect the company’s commitment to advanced procedural medicine.
3. Connected Care
The Connected Care segment continues to be a strategic priority, contributing approximately $3.5bn to the annual revenue. This division represents BD’s commitment to digital health and integrated delivery systems—a critical area for modern healthcare providers looking to optimize patient outcomes through real-time data and connectivity.
4. BioPharma Systems: The Growth Leader
While the BioPharma Systems segment represents the smallest proportion of total revenue at $771m, it is undeniably the company’s "growth engine." Posting a remarkable 17% year-over-year increase, this segment underscores the company’s success in aligning itself with the rapidly expanding biopharmaceutical market, providing the essential delivery systems for modern therapeutics.
Leadership Perspective: Tom Polen on the "New BD"
In his address to shareholders, BD president and CEO Tom Polen framed the last twelve months as a "defining year." His commentary emphasized that the transition was not merely a subtraction of assets, but an additive process for the company’s future capabilities.
"We strengthened our core growth and expanded BD Excellence to elevate our commercial capabilities, accelerate innovation, and drive greater productivity," Polen stated. "We enter fiscal 2027 from a position of strength, with a portfolio built for durable performance and confidence in the long-term growth, earnings, and cash-flow potential of New BD."
Polen’s focus on "BD Excellence"—the company’s internal operational improvement program—suggests that the leadership team is now laser-focused on extracting efficiency from the newly consolidated organization. By simplifying the corporate structure, BD aims to reduce overhead while increasing the velocity of its R&D pipeline.
Financial Implications and Future Outlook
As the company looks toward FY27, the market is closely watching its earnings guidance. BD has projected earnings in the range of $13.10 to $13.30 per share. This forecast suggests that leadership expects the post-spin-off structure to yield higher margins and more predictable cash flows.
Investor Sentiment
The market reaction on 5 November, with the stock price firming up to $214.04, reflects a cautiously optimistic view. With a market capitalization of approximately $58bn, BD is large enough to maintain a significant footprint in global markets, yet streamlined enough to react more nimbly to competitive pressures.
The transition to a more focused medtech player mitigates the risk of being diluted by the cyclical nature of the diagnostic testing market, which often experiences significant volatility based on public health trends. By focusing on surgical, interventional, and drug delivery systems, BD is aligning its future with the demographic reality of an aging global population that requires more frequent, complex medical interventions.
The Broader Industry Context
The move by BD to shed its diagnostic business is part of a wider trend of "specialization" among medical device giants. As the healthcare industry becomes increasingly complex, firms are finding that conglomerates—once the preferred model for stability—are often too sluggish to compete with specialized agile startups or focused competitors.
By divesting to Waters Corporation, BD has not only unlocked shareholder value but has also allowed its diagnostic assets to be integrated into a firm with a deeper specialization in analytical technologies. This creates a "win-win" scenario: Waters expands its diagnostic reach, and BD focuses on its primary mission of advancing the world of health through medical delivery.
Challenges Ahead
Despite the positive outlook, BD faces the inherent challenges of any post-divestiture firm. Integrating the remaining businesses into a more cohesive, high-functioning unit requires operational discipline. The company must prove that it can maintain its 4.6% to 6.7% growth rates in its core segments without the cushion provided by the high-recurring revenue of the diagnostic arm. Furthermore, as healthcare systems worldwide look to cut costs, BD will need to demonstrate that its "connected care" and "interventional" products provide sufficient value-based care to justify their inclusion in hospital budgets.
Conclusion: A New Chapter for BD
The fiscal year 2026 report serves as a bridge between the BD of the past and the "New BD" of the future. The company has successfully navigated one of the largest divestitures in recent medtech history, proving that it can maintain financial growth even amidst radical organizational change.
With a strong performance in its core segments and a clear roadmap for FY27, Becton, Dickinson and Company has set the stage for a period of focused growth. By prioritizing its medical essentials and high-growth biopharma systems, the company is positioning itself not just as a supplier of medical equipment, but as a critical partner in the evolving ecosystem of modern medicine. As the industry watches, the focus will now shift to whether this streamlined approach can truly translate into the long-term, durable performance that management has promised its shareholders.
About the Author
